These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 35034282

  • 1. Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
    Bagardi M, Palermo V, Locatelli C, Colombo FM, Pazzagli L, Brambilla PG.
    Vet Res Commun; 2022 Jun; 46(2):481-486. PubMed ID: 35034282
    [Abstract] [Full Text] [Related]

  • 2. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W.
    J Vet Cardiol; 2022 Jun; 41():99-120. PubMed ID: 35316716
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T.
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N, Wall L, Nolte I, Raue J, Rumstedt K, Pilgram A, Sehn M, Rohn K, Bach JP.
    PLoS One; 2019 Nov; 14(10):e0223164. PubMed ID: 31581204
    [Abstract] [Full Text] [Related]

  • 6. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Nov; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 7. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 8. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
    Pirintr P, Saengklub N, Boonpala P, Hamlin RL, Kijtawornrat A.
    BMC Vet Res; 2023 Oct 12; 19(1):201. PubMed ID: 37821927
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK, DeFrancesco TC, Meurs KM, Papich MG.
    J Vet Intern Med; 2023 Oct 12; 37(6):2003-2010. PubMed ID: 37776546
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE.
    J Vet Intern Med; 2021 Jul 12; 35(4):1673-1687. PubMed ID: 34028078
    [Abstract] [Full Text] [Related]

  • 11. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Jul 12; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Jul 12; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 13. Clinical findings and survival time in dogs with advanced heart failure.
    Beaumier A, Rush JE, Yang VK, Freeman LM.
    J Vet Intern Med; 2018 May 12; 32(3):944-950. PubMed ID: 29635788
    [Abstract] [Full Text] [Related]

  • 14. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 12; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 15. Circulating MiR-30b-5p is upregulated in Cavalier King Charles Spaniels affected by early myxomatous mitral valve disease.
    Bagardi M, Ghilardi S, Zamarian V, Ceciliani F, Brambilla PG, Lecchi C.
    PLoS One; 2022 Nov 12; 17(7):e0266208. PubMed ID: 35816500
    [Abstract] [Full Text] [Related]

  • 16. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan 12; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 17. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
    Sabetti MC, Fidanzio F, Troìa R, Perissinotto L, Romito G, Mazzoldi C, Quintavalla C, Crosara S, Dondi F.
    J Vet Cardiol; 2022 Jun 12; 41():57-69. PubMed ID: 35245876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG.
    J Vet Cardiol; 2015 Jun 12; 17(2):120-8. PubMed ID: 26007710
    [Abstract] [Full Text] [Related]

  • 20. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL, Visser LC, Gunther-Harrington CT, Ontiveros ES, Wittenburg LA, Palm CA, Stern JA.
    J Vet Intern Med; 2022 Nov 12; 36(6):1892-1899. PubMed ID: 36098206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.